APPLICATION OF REPLACEMENT THERAPY WITH PANCREATIN PREPARATIONS IN PATIENTS WITH PANCREATIC CANCER


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Exocrine pancreatic insufficiency (EPI) is a common complication of both benign and malignant diseases of the pancreas. In pancreatic cancer (PCa), development of EPI can be determined by various mechanisms, including block of main pancreatic duct and degradation of exocrine part of organ (due to tumor invasion), and mediated by surgical interventions. In most cases, enzyme replacement therapy with pancreatic enzymes can reduce the severity of symptoms of EPI associated with prostate cancer, extend patient’s diet, improve their nutritional status and quality of life. This article presents the clinical guidelines on the use of enzyme replacement therapy in patients with pancreatic cancer, approved by the Russian Society of Clinical Oncology (RUSSCO).

Толық мәтін

Рұқсат жабық

Авторлар туралы

Yu. Kucheryavy

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Moscow

D. Andreev

SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH

Email: dna-mit8@mail.iu
Teaching Assistant of the Department of Piopedeutics of Internal Diseases and Gastroenterology Moscow

Әдебиет тізімі

  1. Ferlay J, Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359-86.
  2. Shires G.T., Wilfong L.S. Pancreatic Cancer, Cystic Pancreatic Neoplasms, and Other Nonendocrine Pancreatic Tumors. In.: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. Edited by Mark Feldman, Lawrence S. Friedman, Laurence J. Brandt. 10th ed. 2015.
  3. Cancer Research UK [Internet]. Twenty most common causes of cancer death. 2012. http:// www.cancerresearchuk.org/cancer-info/can-cerstats/mortality/cancerdeaths/#Twenty (accessed Sept 2015).
  4. Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J. Gastroenterol. 2015;21(31):9297-316.
  5. Mayo Clinic gastroenterology and hepatology board review. Editor-in-chief, Stephen C. Hauser; associate editors, Amy S. Oxentenko, William Sanchez. 5th edition. 2015.
  6. Evans B, Erickson B., Ritch P. Borderline resectable pancreatic cancer: Definitions and the importance of multimodal therapy. Ann. Surg. Oncol. 2010;17:2803-805.
  7. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Дичева ДТ, Гуртовенко И.Ю., Баева Т.А. Хронический панкреатит: новые подходы к диагностике и терапии. М., 2014.
  8. Kucheryavy Yu.A., Andreev D.N. Nutritional Status in Patients with Chronic Pancreatitis. J. Nutrition. Ther. 2014;3(3):122-32.
  9. Дичева Д.Т., Андреев Д.Н. Синдром внешнесекреторной недостаточности поджелудочной железы: алгоритм терапевтической тактики. Справочник поликлинического врача. 2014;1:22-3.
  10. Bartel M.J., Asbun H., Stauffer J., Raimondo M. Pancreatic exocrine insufficiency in pancreatic cancer: A review of the literature. Dig. Liver Dis. 2015;47(12):1013-20.
  11. Кучерявый Ю.А. Внешнесекреторная панкреатическая недостаточность после оперативных вмешательств на желудке и поджелудочной железе. Хирургия. 2012;1:42-6.
  12. Ihse I., Arnesjö B., Kugelberg C., Lilja P. Intestinal activities of trypsin, lipase, and phospholipase after a test meal: an evaluation of 474 examinations. Scand. J. Gastroenterol. 1977;12:663-68.
  13. Kato H., Nakao A., Kishimoto W., Nonami T., Harada A., Hayakawa T., Takagi H. 13C-labeled trioctanoin breath test for exocrine pancreatic function test in patients after pancreatoduodenectomy. Am. J. Gastroenterol. 1993;88:64-9.
  14. Sato N., Yamaguchi K., Yokohata K., Shimizu S., Morisaki T., Chijiiwa K., Tanaka M. Short-term and long-term pancreatic exocrine and endocrine functions after pancreatectomy. Dig. Dis. Sci. 1998;43:2616-21.
  15. Matsumoto J. Traverso L.W. Exocrine function following the Whipple operation as assessed by stool elastase. J. Gastrointest. Surg. 2006;10:1225-29.
  16. Perez M.M., Newcomer A.D., Moertel C.G., Go V.L., Dimagno E.P. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer. 1983; 52(2):346-52.
  17. Sikkens E.C., Cahen D.L., de Wit J., Looman C.W., van Eijck C., Bruno M.J. A prospective assessment of the natural course of the exocrine pancreatic function in patients with a pancreatic head tumor. J. Clin. Gastroenterol. 2014;48:e43-46.
  18. Damerla V., Gotlieb V., Larson H., Saif M.W. Pancreatic enzyme supplementation in pancreatic cancer. J. Support Oncol. 2008; 6(8):393-96.
  19. Reuben D.B., Mor V., Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch. Intern. Med 1988;148:1586-91.
  20. Landers A., Muircroft W., Brown H. Pancreatic enzyme replacement therapy (PERT) for malabsorption in patients with metastatic pancreatic cancer. BMJ Support Palliat. Care. 2014;6(1):75-9.
  21. Gooden H.M., White K.J. Pancreatic cancer and supportive care-pancreatic exocrine insufficiency negatively impacts on quality of life. Support Care Cancer. 2013;21(7):1835-41.
  22. Bruno M.J., Haverkort E.B., Tijssen G.P., Tytgat G.N., van Leeuwen D.J. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut. 1998;42:92-6.
  23. Dominguez-MunozJ.E.,NietoL.,Iglesias-GarciaJ. Pancreatic enzyme replacement therapy and nutritional advice are associated with longer survival in patients with unresectable pancreatic cancer. Pancreas. 2013;42:1347.
  24. Seiler C.M., Izbicki J., Varga-Szabo L., Czako L., Fiok J., Sperti C., Lerch M.M., Pezzilli R., Vasileva G., Pap A., Varga M., Friess H. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension. Aliment. Pharmacol. Ther. 2013;37:691-702.
  25. Dominguez-Munoz J.E. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr. Gastroenterol. Rep. 2007;9(2):116-22.
  26. Kuhnelt P., Mundlos S., Adler G. Effect of pellet size of a pancreas enzyme preparation on duodenal lipolytic activity. Z. Gastroenterol. 1991;29(9):417-21.
  27. Ивашкин В.Т., Маев И.В., Охлобыстин А.В., Кучерявый Ю.А. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению хронического панкреатита. РЖГГК. 2014;24(4):70-97.
  28. Андреев Д.Н., Бордин Д.С., Кучерявый Ю.А., Маев И.В. Практические рекомендации по назначению заместительной ферментной терапии у пациентов с раком поджелудочной железы. Злокачественные опухоли. 2015; 4S:435-8.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2016

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>